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Abstract
Introduction Immediate precursors of bone-resorbing
osteoclasts are cells of the monocyte/macrophage lineage.
Particularly during clinical conditions showing bone loss, it
would appear that osteoclast precursors are mobilized from
bone marrow into the circulation prior to entering tissues
undergoing such loss. The observed heterogeneity of peripheral
blood monocytes has led to the notion that different monocyte
subpopulations may have special or restricted functions,
including as osteoclast precursors.
Methods Human peripheral blood monocytes were sorted
based upon their degree of proliferation and cultured in
macrophage colony-stimulating factor (M-CSF or CSF-1) and
receptor activator of nuclear factor-kappa-B ligand (RANKL).
Results The monocyte subpopulation that is capable of
proliferation gave rise to significantly more multinucleated, bone-
resorbing osteoclasts than the bulk of the monocytes.
Conclusions Human peripheral blood osteoclast precursors
reside in the proliferative monocyte subpopulation.
Introduction
Rheumatoid arthritis (RA) is a chronic disease that is charac-
terized by joint inflammation and profound focal and general-
ized bone loss due to the action of osteoclasts [1,2].
Multinucleated osteoclasts derive from monocyte/macro-
phage lineage precursors; two key mediators controlling their
development are macrophage colony-stimulating factor (M-
CSF or CSF-1) and receptor activator of nuclear factor-kappa-
B ligand (RANKL) [3-5]. Human osteoclast precursors have
been shown to be present at low frequency in normal periph-
eral blood [6-8]. It now appears that peripheral blood mono-
cytes, which derive from bone marrow precursors, are
heterogeneous as judged by criteria such as surface marker
expression, size, and function [9]. For example, in the human,
there is a minor subpopulation of monocytes which is CD14lo
CD16+ [10] and which has been implicated in inflammation
and cancer [11-13]; in the mouse, there is a lot of recent inter-
est in monocyte subpopulations that appear to have different
roles during inflammatory reactions as manifested, for exam-
ple, by their ability to migrate to sites of inflammation [14].
Human osteoclast precursors have recently been shown to
reside in the CD14+ CD16- monocyte subpopulation of normal
donors [15]. Blood samples from psoriatic arthritis patients,
particularly those with bone erosions visible on plain radio-
graphs, exhibit an increase in osteoclast precursors compared
with those from healthy controls [16]; these precursors were
recently reported to reside in the CD14lo CD16+ monocyte
subset, leading the authors to suggest that osteoclasts are
derived from distinct monocyte subsets in these patients and
in healthy individuals [17].
Human monocytes are commonly considered to be non-prolif-
erating [18]; however, we and others have defined a subpop-
ulation of human monocytes which is capable of proliferating
in vitro (for example, in response to M-CSF) [19-25]. This pop-
ulation has been referred to as proliferative monocytes (PMs),
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which were shown recently to have the phenotype CD14+
CD16- CD64+ CD33+ CD13lo c-Fms+ prior to culture [25]. It
was previously suggested that PMs might be able to migrate
into inflamed tissues and possibly undergo local proliferation
there [19,25]. During these prior phenotyping studies, it was
noticed in passing that, following culture and sorting by flow
cytometry, the PMs, from the few donors studied, could give
rise to tartrate-resistant acid phosphatase-positive (TRAP+)
multinucleated cells upon culture in M-CSF + RANKL [25].
Based on this preliminary observation and the likelihood that
the PMs represent a relatively less mature monocyte popula-
tion on account of their ability to proliferate, it was reasoned
that they may retain differentiation capability and therefore
contain the osteoclast precursors. We present evidence here
for this concept for the peripheral blood from normal donors.
Materials and methods
Peripheral blood mononuclear cell isolation, CFSE 
labeling, and cell culture
Peripheral blood mononuclear cells (PBMCs) were isolated
following Ficoll centrifugation and labeled with carboxyfluores-
cein diacetate-succinimidyl ester (CFSE) (Molecular Probes
Inc., now part of Invitrogen Corporation, Carlsbad, CA, USA)
as described previously [25]. CFSE-labeled PBMCs were
seeded onto non-treated 100-mm dishes (Iwaki; Asahi Techno
Glass Corporation, Funabasi City, Japan) at a concentration of
3 to 5 × 107 cells per dish and allowed to adhere overnight in
alpha-minimum essential medium (α-MEM) (JRH Biosciences,
now part of SAFC Biosciences, Lenexa, KS, USA) containing
L-glutamine (2 mM; Invitrogen Corporation) and penicillin (100
U/mL)/streptomycin (100 μg/mL) (Invitrogen Corporation).
Non-adherent cells were washed away, and new medium was
added (α-MEM containing 3% heat-inactivated fetal bovine
serum [Hi-FBS]) (CSL, Parkville, Victoria, Australia) with M-
CSF (8,000 U/mL) (Chiron, Emeryville, CA, USA). These cul-
tures were incubated at 37°C in 5% CO2 for 9 days with a
change of medium and removal of non-adherent cells every 3
days.
Cell sorting
The CFSE-stained cells were incubated in ice-cold phos-
phate-buffered saline (PBS) for 30 minutes and harvested by
gentle scraping with a rubber policeman. Cells were resus-
pended in fluorescence-activated cell sorting (FACS) buffer
(PBS containing 1% FBS) (Invitrogen Corporation) and 1 mM
ethylenediaminetetraacetic acid (EDTA) (Ajax Chemicals,
Cheltenham, Victoria, Australia) at a density of 107 cells per
millilitre. Propidium iodide solution (3 μL of 1 mg/mL; Sigma-
Aldrich, St. Louis, MO, USA) was added immediately prior to
sorting. CFSE fluorescence levels were determined by flow
cytometry. The appearance of a peak with high fluorescence
intensity (CFSEhi) indicated the cells that had not divided. Half
the fluorescence intensity (CFSElo) indicated cells that have
undergone one division. The existence of multiple peaks in
some samples indicated multiple cell divisions in those popu-
lations [25]. CFSE-labeled cells were then sorted using a
FACSVantage SE (BD Biosciences, San Jose, CA, USA).
Osteoclast generation from peripheral blood 
mononuclear cells
Sorted cells were cultured at 3 × 104 cells per well (in α-MEM
and 3% Hi-FBS) in M-CSF (8,000 U/mL; Chiron) with or with-
out RANKL (50 ng/mL; PeproTech, Rocky Hill, NJ, USA).
These cultures were incubated at 37°C in 5% CO2 for up to
21 days; the culture medium, including the relevant mediators,
was changed twice per week. For the bone resorption assay,
bone slices (horse cortical femur) were added to the well prior
to the addition of the cells.
Tartrate-resistant acid phosphatase staining
Osteoclast differentiation was determined firstly by TRAP
staining following fixation in formaldehyde and acetone/alco-
hol as described previously [26]. Briefly, following fixation,
cells were stained with freshly prepared TRAP staining solu-
tion (naphthol AS-MX phosphate, fast red violet LB salt, and
potassium sodium tartrate). Osteoclast formation was evalu-
ated by counting the TRAP+ multinucleated (n ≥ 3) cells.
mRNA extraction and quantitative reverse transcription-
polymerase chain reaction analyses
Cells were plated at a density of 5 × 105 in 3 mL/well of
medium (α-MEM and 3% Hi-FBS) in the presence of M-CSF
(8,000 U/mL) with or without RANKL (50 ng/mL) in 6-cm tis-
sue culture dishes (Becton, Dickinson and Company, Franklin
Lakes, NJ, USA). Cells were incubated for 14 days with a com-
plete change of medium every 3 to 4 days. Total RNA was iso-
lated with the RNAeasy kit (Qiagen Inc., Valencia, CA, USA) in
accordance with the instructions of the manufacturer. cDNAs
were synthesized as described previously [27]. Pre-Devel-
oped TaqMan Assay Reagents (Applied Biosystems,
Scoresby, Victoria, Australia) were used for cDNA sequence
analysis for calcitonin receptor (CTR) and cathepsin K (Cath
K). Quantitative polymerase chain reaction (PCR) analyses
were used to quantify transcripts with the ABI Prism 7900 HT
Sequence Detection System (Applied Biosystems) as
described previously [27]. For the PCR analyses, fluores-
cence from each sample was measured once each cycle dur-
ing PCR and plotted against cycle number; the earlier a signal
appeared (at a lower cycle number), the higher the concentra-
tion of the template. The cycle threshold (Ct) number was
used to indicate gene expression.
Pit formation assay
Cells were removed from bone slices by brief sonication
(approximately 30 seconds) and lysed in 1% Triton-X 100 for
30 minutes. Haematoxylin was applied to the resorbed surface
of each slice for 1 minute and then the slices were washed
three or four times with tap water. The residual stain was
removed by wiping against absorbent paper. Resorption was
observed by transmission light microscopy. Total pit area andAvailable online http://arthritis-research.com/content/11/1/R23
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total bone area were measured in 10 randomly selected areas
for two or three bone slices by the Scion Image analysis pro-
gram (Scion Corporation, Frederick, MD, USA), and the per-
centage pit area in each group was calculated [28].
Statistical analysis
Data are presented as mean ± standard error. Significant dif-
ferences were determined using the paired Student t test; a P
value of less than or equal to 0.05 was considered significant.
Results
Proliferative monocytes contain precursors of tartrate-
resistant acid phosphatase-positive multinucleated cells
After culture in M-CSF, adherent, CFSE-labeled PBMCs
could be sorted, based on their differing fluorescence intensi-
ties due to the number of cell divisions, into the PM and non-
proliferative (NP) populations [25] (Figure 1). Preliminary data
using PBMCs from three donors indicated that the former, pre-
dominantly spindle-shaped, population contained the bulk of
the precursors which could be converted by culture in M-CSF
+ RANKL into TRAP+ multinucleated cells with more intense
TRAP staining (that is, possibly osteoclasts) [25]. In a more
complete study, we now present data (Figure 2) for the
number of TRAP+ multinucleated (n ≥ 3) cells obtained from
PBMCs from 13 donors and it can be seen that in general
there were more of such cells derived from the PM population
(P < 0.001) than from the NP monocyte population, an effect
requiring the presence of RANKL; some multinucleated (n ≥ 3)
cells could be observed even at day 7 in the PM cultures in the
presence of M-CSF and RANKL (data not shown).
Higher osteoclast-associated gene expression in the 
proliferative monocyte population following culture in 
M-CSF and RANKL
Even though it was presented above that significantly more
TRAP+ multinucleated cells can be obtained from the PM pop-
ulation, actual osteoclast differentiation needs to be confirmed
as osteoclasts and macrophage polykaryons are morphologi-
cally similar [29]; in addition, TRAP staining does not distin-
guish very well between such populations in the human. We
therefore firstly measured the expression of certain genes
whose products are associated with osteoclast function. In
Figure 3, the results from four donors for CTR and Cath K
mRNA expression following culture in M-CSF + RANKL for 14
days are provided; it can be noted that there was significantly
more expression of these osteoclast-specific genes from the
PM population, which required RANKL to be present (data not
shown). Consistent again with the greater osteoclastogenic
potential of the PMs, their progeny, following culture in M-CSF
+ RANKL, had significantly greater RANK expression when
measured at 14 days, at least at the gene level, when com-
pared with that from the NP cells (data not shown).
Higher bone resorption in the proliferative monocyte 
population following culture in M-CSF and RANKL
To confirm the functional activity of the multinucleated cells
produced, bone resorption was measured next. The PM and
NP populations were cultured in tissue culture dishes contain-
ing bone slices in the presence of M-CSF + RANKL. After 3
Figure 1
Sorting proliferative monocyte (PM) and non-proliferative (NP) popula- tion cells after carboxyfluorescein diacetate-succinimidyl ester (CFSE)  labeling and culture Sorting proliferative monocyte (PM) and non-proliferative (NP) popula-
tion cells after carboxyfluorescein diacetate-succinimidyl ester (CFSE) 
labeling and culture. CFSE-labeled peripheral blood mononuclear cells 
were cultured in alpha-minimum essential medium + 3% heat-inacti-
vated fetal bovine serum containing macrophage colony-stimulating 
factor (8,000 U/mL) in non-treated dishes for 9 days. The adherent 
cells were then sorted based on their CFSE fluorescence intensity as 
PM (CFSElo) and NP (CFSEhi) populations [25].
Figure 2
Proliferative monocytes (PMs) contain precursors of tartrate-resistant  acid phosphatase-positive (TRAP+) multinucleated cells (MNCs) Proliferative monocytes (PMs) contain precursors of tartrate-resistant 
acid phosphatase-positive (TRAP+) multinucleated cells (MNCs). Non-
proliferative (NP) and PM subpopulations from 13 donors, sorted as in 
Figure 1, were cultured in duplicate or triplicate cultures in macrophage 
colony-stimulating factor (M-CSF) (8,000 U/mL) and receptor activator 
of nuclear factor-kappa-B ligand (RANKL) (50 ng/mL) for 21 days; 
because insufficient cells were available, the two starting populations 
from fewer donors were also cultured in M-CSF alone. TRAP+ MNCs 
were counted. The mean number of such cells was significantly higher 
in the PM-derived cells cultured in M-CSF and RANKL compared with 
the NP-derived population (*P < 0.001). M, macrophage colony-stimu-
lating factor; R, receptor activator of nuclear factor-kappa-B ligand.Arthritis Research & Therapy    Vol 11 No 1    Lari et al.
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weeks, numerous resorption lacunae were found distributed
over the surface of the bone slices in the PM cultures. How-
ever, only a few small resorption pits were observed in the
bone slices cultured with NP cells under the same conditions
(Figure 4).
Discussion
Under steady-state conditions, osteoclastogenesis and bone
remodeling occur mainly in the bone marrow. Osteoclast pre-
cursors can be mobilized from bone marrow into blood and
then into tissues, particularly in some conditions involving
bone loss at diseased sites (for example, RA) [30,31]. At an
early stage of differentiation, they are also able to give rise to
different myeloid populations [32], whereas at a later stage
their differentiation involves M-CSF-dependent action on c-
Fms+ populations [33].
The heterogeneity of peripheral blood monocytes has led to
the concept that there may be distinct subpopulations of cells
with specialized functions [10,14,34,35]. For example, for the
human, it is known that only a small proportion of monocytes
can differentiate into osteoclasts [36,37]. Likewise, it is known
that a small proportion of CD14+ human monocytes (that is,
PMs) can proliferate in vitro [19,25]; because of their ability to
Figure 3
Osteoclast gene expression in differentiated proliferative monocyte  (PM) and non-proliferative (NP) subpopulations Osteoclast gene expression in differentiated proliferative monocyte 
(PM) and non-proliferative (NP) subpopulations. NP and PM subpopu-
lations, sorted as in Figure 1, were cultured for 14 days in macrophage 
colony-stimulating factor (8,000 U/mL) and receptor activator of 
nuclear factor-kappa-B ligand (50 ng/mL). Calcitonin receptor (CTR) 
and cathepsin K (Cath K) mRNA expression were measured by quanti-
tative polymerase chain reaction. Samples from four individual donors 
were tested in triplicate, and data were normalized to 18S expression 
for each gene. Values are means of cycle threshold (Ct) numbers that 
were obtained in each sample ± standard error. The mean values for 
the PM population were significantly lower than those for the corre-
spondingly treated NP population from the same donor (P ≤ 0.05).
Figure 4
Precursors of bone-resorbing cells reside in the proliferative monocyte  (PM) population Precursors of bone-resorbing cells reside in the proliferative monocyte 
(PM) population. Sorted non-proliferative (NP) and PM populations 
(Figure 1) were cultured on bovine bone (3 × 104 cells per slice) for 21 
days in the presence of macrophage colony-stimulating factor (8,000 
U/mL) and receptor activator of nuclear factor-kappa-B ligand (50 ng/
mL). (a) The bone slices were stained with haematoxylin (magnification 
× 200). Arrows indicate pits on the bone surface. (b) Resorption pit 
area measured for four donors (see 'Higher bone resorption in the pro-
liferative monocyte population following culture in M-CSF and RANKL' 
section). Values are means of percentage of resorbed bone ± standard 
error. For each donor, the mean values for the PM group are signifi-
cantly greater than those for the correspondingly treated NP cells (P < 
0.05).Available online http://arthritis-research.com/content/11/1/R23
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proliferate, it was reasoned that this less mature population,
possibly representing cells recently mobilized from bone mar-
row, may be able to differentiate into different macrophage lin-
eage populations, such as osteoclasts, under appropriate
conditions.
Taking advantage of the relative ability of monocyte popula-
tions to undergo proliferation, we were able to show above
that, for the blood from 13 donors, osteoclast precursors
reside predominantly in the PM population and could be
detected even after proliferation in M-CSF. Following further
culture in M-CSF and RANKL, the resultant population con-
taining the multinucleated progeny showed increased expres-
sion of certain osteoclast markers (CTR, Cath K, and RANK)
and an ability to resorb bone. These findings are consistent
with the concept that the PMs represent a less mature popu-
lation, when compared with the bulk of the human peripheral
blood monocytes [19-21], with some cells in the PM fraction
at least retaining an ability to differentiate into osteoclasts. The
data presented are consistent with prior observations that
both the PM population [19,25] and osteoclast precursors
[15] from normal individuals reside in the CD14+ CD16- mono-
cytes rather than in the CD14lo CD16+ population, that osteo-
clastic cells can be generated from proliferating dendritic cell
precursors in human peripheral blood [38], and that there is an
early increase in the percentage of human peripheral blood
osteoclast precursors entering S phase during their in vitro dif-
ferentiation in M-CSF + RANKL [39]. It is possible that the
PMs can differentiate while in the blood into NP monocytes
with reduced proliferative and differentiation potential, per-
haps under the influence of circulating M-CSF.
It is intriguing that, in psoriatic arthritis, the opposite finding
has been made in that the increased numbers of peripheral
blood osteoclast precursors noted were located in the CD16+
population [17]. It would be worth knowing whether the PM
population also increases in this and perhaps other inflamma-
tory conditions and whether they begin to express higher
CD16 levels in vivo. We suggest again [25] that functional cri-
teria, such as PM status, have an advantage over surface
marker phenotyping in that they avoid the difficulty in defining,
for example, for monocyte populations whether modulation in
the expression of a particular surface marker reflects differen-
tiation or activation.
Conclusion
In summary, it has been shown here that human peripheral
blood osteoclast precursors reside in the PM subpopulation,
which is presumably a relatively less mature subpopulation
and therefore possibly recently mobilized from bone marrow
[19-21]. It has been proposed before [19-21,25] that, upon
migration into inflammatory lesions, the PMs may contribute to
the local macrophage proliferation which can be observed
[40,41]. It is also possible that they could reside as osteoclast
precursors in the synovial macrophage population within RA
joints [30] which have been shown capable of differentiation
into osteoclasts [42,43].
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